NCT06669130Not yet recruitingNot Applicable
Efficacy and Safety of Xiangtong TM Full Degradation Sinus Drug Stent System
The First Affiliated Hospital with Nanjing Medical University0 sites50 target enrollmentStarted: December 1, 2024Last updated:
Conditions
Interventions
Trial Snapshot
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Enrollment
- 50
- Primary Endpoint
- Postoperative reintervention rates based on imaging evaluations
Study Overview
Brief Summary
Xiangtong® Fully Degradable Sinus Drug Stent System is a high-tech medical device independently developed by Puyi Bio, specially designed for patients with chronic rhinosinusitis (CRS) undergoing endoscopic sinus surgery (ESS).The product is implanted into the target site during and after surgery, which not only supports the separation of the wound and fixes the repaired mucosal flap, but also controls edema, prevents adhesions, maintains smooth drainage, and sustains the target site to fight against inflammation and promotes healing by means of slow-release hormones.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 65 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Subjects are 18-65 years of age, male or non-pregnant female. The subject/legally authorized representative understands the purpose and procedures of the trial and voluntarily signs an informed consent form.
- •Subjects must meet the diagnostic guidelines for chronic rhinosinusitis, have a confirmed diagnosis of bilateral chronic rhinosinusitis, and have a CT scan confirming bilateral Lund-Mackay scores >6 (CT scan within 3 months prior to surgery is valid).
- •Female subjects who are not breastfeeding at the time of the screening visit and who do not plan to breastfeed or become pregnant for up to one year after the starting point.
- •Subject has not participated in another clinical trial in the previous 3 months and agrees not to participate in another clinical trial until the endpoints of this trial have been met.
Exclusion Criteria
- •Subject has a known allergic reaction or contraindication to the device material and its degradation products (mometasone acid, levulinic acid, racemic polylactic acid, propyl lactate, lactic acid).
- •The subject is on long-term oral hormonal medications.
- •The subject is receiving immunosuppressive therapy or has a known immunosuppressive or autoimmune disease: the subject has diabetes mellitus.
- •The subject has or has had glaucoma or high intraocular pressure.
- •The subject has cataracts.
- •The subject has an artificial eye.
- •Acute bacterial sinusitis and acute fungal sinusitis.
- •Subject has a life expectancy of less than 12 months.
- •Subject has participated in a clinical trial of another drug or device that did not meet the primary study endpoint: Subject is unable or unwilling to participate in this trial.
Arms & Interventions
Xiangtong TM full degradation sinus drug stent system
Experimental
Intervention: Xiangtong TM full degradation sinus drug stent system (Device)
nasopore
Placebo Comparator
Intervention: nasopore (Device)
Outcomes
Primary Outcomes
Postoperative reintervention rates based on imaging evaluations
Time Frame: 30 days after operation
Secondary Outcomes
No secondary outcomes reported
Investigators
Similar Trials
Recruiting
Not Applicable
Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical PracticePercutaneous Transluminal Coronary AngioplastyCoronary Artery DiseaseNCT01186133Seung-Jung Park50,000
Unknown
Phase 2
China Made Sirolimus Eluting Stent for Intermediate LesionCoronary Artery DiseaseNCT01375296Shanghai Jiao Tong University School of Medicine600
Completed
Phase 4
A Single Center Prospective Randomized Controlled Clinical Study of JANUS Stent in Patients With Coronary Artery DiseaseCoronary Heart DiseaseNCT00406523Shenyang Northern Hospital
Active, not recruiting
Not Applicable
Evaluation of Effectiveness and Safety of XIENCE Sierra in Routine Clinical PracticeCoronary DiseaseCoronary Artery DiseaseNCT03967158Seung-Jung Park2,000
Completed
Not Applicable
The Complete® Self-Expanding Stent and Stent Delivery System RegistryPeripheral Vascular DiseaseNCT00730730Medtronic Endovascular50